Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus anlotinib for cervical cancer after failure of standard therapy
ChiCTR2400093200Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and anlotinib in Cervical Cancer (CC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective Response Rate. Started Nov 2024; status: completed.
02
Drugs
tislelizumabanlotinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2400093200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093200.